NCT04521361已完成1 期
Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium-223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 46
- 试验地点
- 12
- 主要终点
- AUC of radium-223 in tumor-free bone after 3 doses
研究概览
简要总结
In this study researcher want to gain more information on how the study drug (radium-223) is distributed in the bone, particularly in the tumor free bone in participants with prostate cancer. The study plans to enroll 60 patients with the age of at least 18 years and suffering from prostate cancer which has spread to the bones. Researcher will divide the study participants into 2 groups. Patients in Group 1 should have up to 6 bone metastases and patients for group 2 should have more than 6 bone metastases. The study medication will be given as injection into a vein every 4 weeks up to a maximum of 6 times. To study how radium distributes in the body and particularly in the bones, participants will undergo after study medication intake MRI or CT Scans (imaging techniques).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participants who have histologically confirmed adenocarcinoma of the prostate.
- •Participants with bone metastatic CRPC, progressing after 1 or 2 prior lines of systemic treatment for metastatic prostate cancer (including prior treatment for metastatic hormone sensitive prostate mHSPC or metastatic castration resistant prostate cancer mCRPC).
- •Participants with at least 2 bone metastases on Tc 99m phosphonate whole body planar bone scans at Screening.
- •Documented progression of mCRPC. Disease progression is defined by at least one of the following criteria: a. PCWG3 criteria (defined as 2 consecutive increases in PSA over a previous reference value measured at least one week prior, with a minimal start value of 1.0 ng/mL) or b. ≥2 new bone lesions (according to PCWG3 bone scan criteria) or c. Radiological progression according to RECIST, version 1.
- •Ability to participate in the required study procedures including all scanning procedures and ability to control pain to ensure tolerance and completion of the necessary scanning procedures.
- •Maintenance of medical castration or surgical castration with testosterone less than 50 ng/dL (1.7 nmol/L). If the participant is being treated with luteinizing hormone releasing hormone (LHRH) agonists or antagonists (participant who has not undergone orchiectomy), this therapy must have been initiated at least 4 weeks prior to start of Screening and must be continued throughout the study.
- •Participants must be on a bone health agent prior to the first dose of radium-223 dichloride. Participants with at least 6 months of prior bone health agent (BHA) treatment are preferred.
- •Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or
- •Life expectancy ≥6 months.
排除标准
- •Any chronic medical condition requiring continuous systemic corticosteroid treatment at a higher dose than 5 mg prednisone / prednisolone twice daily.
- •Pathological finding consistent with neuroendocrine features small cell carcinoma of the prostate.
- •Metastatic bone deposits extend of disease (EOD) grades 0 or 4 (according to centrally assessed Tc 99m phosphonate planar bone scans during Screening).
- •History of visceral metastasis, or presence of visceral metastasis detected by screening imaging examinations (according to central review at screening).
- •Other malignancy treated within the last 5 years (except non-melanoma skin cancer or low-grade superficial bladder cancer).
- •Imminent spinal cord compression based on clinical findings and / or magnetic resonance imaging (MRI). - Participants with history of spinal cord compression should have completely recovered.
- •Active or symptomatic viral hepatitis
- •Inability to tolerate any of the other imaging procedures in the study (ie, bone SPECT/CT and planar bone scans with a Tc 99m phosphonate radiotracer, DXA scan, radium-223 SPECT/CT scans).
- •Any condition, which in the opinion of the investigator would preclude participation in this trial.
- •Hypersensitivity to radium-223 dichloride.
- •Blood transfusion or erythropoietin stimulating agents 4 weeks prior to start of Screening and during the whole Screening period before enrollment into the cohort.
- •Prior administration of an investigational therapeutic for CRPC.
研究组 & 干预措施
Patients with Low extent of disease
Experimental
Adult men with bone mCRPC having < 6 bone metastases
干预措施: Radium-223 dichloride (Xofigo, BAY88-8223) (Drug)
Patients with High extent of disease
Experimental
Adult men with bone mCRPC having ≥ 6 bone metastases
干预措施: Radium-223 dichloride (Xofigo, BAY88-8223) (Drug)
结局指标
主要结局
AUC of radium-223 in tumor-free bone after 3 doses
时间窗: At 4, 24 and 144 hours post injection at Cycle 3 ( total duration of one cycle is 28 days).
The uptake of radium-223 in bone is determined with single-photon emission tomography / computed tomography (SPECT/CT).
次要结局
- AUC of radium-223 in tumor-free bone after single dose(At 4, 24 and 144 hours post injection at Cycle 1 ( total duration of one cycle is 28 days).)
- AUC of radium-223 in tumor-free bone after 6 doses(At 4, 24 and 144 hours post injection at Cycle 6 ( total duration of one cycle is 28 days).)
研究者
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)Non-small Cell Lung Cancer (NSCLC)NCT05585320Immuneering Corporation209
招募中
2 期
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Carcinoma, HepatocellularNCT06349980Shanghai Henlius Biotech117
已完成
早期 1 期
Exploratory and Safety Study of [F-18]W372Alzheimer's DiseaseNCT00954369Siemens Molecular Imaging24
已完成
2 期
A Study of ICP-022 in Patients With R/R DLBCLDiffuse Large B Cell LymphomaNCT04438005Beijing InnoCare Pharma Tech Co., Ltd.3
招募中
1 期
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentAdvanced or Metastatic Solid TumorLiver FailureNCT04617522Gilead Sciences30